Phaseline

Targets › MUCIN16

MUCIN16: drug programs, companies and trials

1 program from 1 company in 5 trials: 3 Phase 2, 2 Phase 1; Oncology; next expected readout May 2027.

Open in Phaseline: the race on MUCIN16, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Regeneron PharmaceuticalsUbamatamab
Anti-MUC16 monoclonal antibody
MUCIN16Phase 2Ovarian Cancer; Non Small Cell Lung Cancer; Recurrent Ovarian Cancer; SMARCB1-Deficient MalignanciesMay 2027

Conditions

Ovarian Cancer (2) Non Small Cell Lung Cancer (1) Recurrent Ovarian Cancer (1) SMARCB1-Deficient Malignancies (1)

Modalities

antibody (1)

Companies

Regeneron Pharmaceuticals (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.